1. Scaroni C, Zilio M, Foti M, Boscaro M. Endocr Rev. 2017;38(3):189-219. doi:10.1210/er.2016-1105 2. Defronzo RA. Banting Lecture. Diabetes. 2009;58(4):773-795. doi:10.2337/db09-9028 3. Barbot M, Ceccato F, Scaroni C. Front Endocrinol (Lausanne). 2018;9:284. doi:10.3389/fendo.2018.00284 4. Pivonello R, De Leo M, Vitale P, et al. Neuroendocrinology. 2010;92(suppl 1):77-81. doi:10.1159/000314319 5. Schernthaner-Reiter MH, Wolf P, Vila G, Luger A. Front Endocrinol (Lausanne). 2021;12:626427. doi:10.3389/fendo.2021.626427 6. Buse JB, Kahn SE, Aroda VR, et al. Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes: updated results from CATALYST part 1 [symposium]. Presented by Fonseca, V. at the 22nd World Congress Insulin Resistance Diabetes & Cardiovascular Disease; December 12-14, 2024; Los Angeles, CA. 7. Elhassan YS, Alahdab F, Prete A, et al. Ann Intern Med. 2019;171(2):107-116. doi:10.7326/M18-3630